BioSpace News Archive

Enlivex Therapeutics Ltd. today announced that the Danish Medicines Agency (DKMA) authorized the expansion into Denmark of the Company’s multi-country, randomized, controlled Phase I/II trial evaluating Allocetra TM in up to 160 patients with moderate to severe knee osteoarthritis.

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, April 30, 2024.

Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced that it has filed a provisional patent application pertaining to the recent advancements and optimizations Monopar has achieved with its MNPR-101 radiopharmaceutical program.

Excision BioTherapeutics, Inc. today announced that it will make an oral presentation on April 24, 2024, at CRISPRMED24, the first CRISPR Medicine Conference, which is being held from April 23-25 in Copenhagen, Denmark.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, launched the first all-in-one, validated genetic stability assay of its kind.

CSafe , an active and passive temperature-controlled shipping solutions provider for the biopharmaceutical industry, proudly announces the launch of a new line of cryogenic multi-use dewars for the cell and gene therapy market.

Arrivo Bio announced today a significant step forward in the fight against major depressive disorder (MDD) with the dosing of the first patient in the SP-624-202 clinical trial.

Telomir Pharmaceuticals, Inc.(Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on Telomir-1 as a potential treatment for age-related conditions, today recapped its presentation of compelling pre-clinical data on Telomir-1 at a high-profile event hosted at the National Press Club in Washington, D.C., on April 15, 2024.

Glucotrack, Inc., a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced that it is expanding its glucose monitoring technology to include measuring glucose in the epidural space.

Aphaia Pharma today announced that Steffen-Sebastian Bolz, M.D., Ph.D., Chief Scientific Officer of Aphaia Pharma, will participate in a panel discussion at the 10th LSX World Congress, taking place April 29-30, 2024 in London, England.